A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma

A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma - THP-1

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048724

Enrollment

Registered

2022-08-22

Start date

1999-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aggressive lymphoma

Interventions

For THP-COP therapy, 50mg/m2 THP, 750 mg/m2 CPA, and 1.4mg/m2 VCR (max 2.0 mg/body) were administered on day 1, and 100mg/body PDN was administered on days 1~5 in accordance with the CHOP regimen regu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 70 to 79 years of age, previously untreated, Working Formulation D through H and J , clinical stage I disease with a bulky mass or stage II,III,IV disease according to the Ann Arbor classification , Eastern Cooperative Oncology Group performance status of 0,1

Exclusion criteria

Exclusion criteria: any other malignancies, mental illness, myocardial infarction or angina history, central nervous system infiltration, uncontrollable diabetes, human immunodeficiency virus infection, hepatitis B virus surface antigen, and/or hepatitis C virus antibody positivity were excluded.

Design outcomes

Primary

Measure	Time frame
complete response rate	—

Secondary

Measure	Time frame
Failure free survival, progression free survival, safty	—

Countries

Japan

Contacts

Public ContactKen Ohmachi

Tokai university, school of medicine hematology

8jmmd004@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026